Latest revenue
$20.0M
as of 2026-03-31
Latest net income
$-33.0M
as of 2026-03-31
Net margin
-164.6%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ADCT is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $101.3M
- Enterprise value
- $-14.0M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $4.97
- 52-wk low
- $1.01
- Beta
- —
- Shares out
- 98.9M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Item 1. Business Overview ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (“ADCs”), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC. ZYNLONTA received accelerated approval from the U.S. Food and Drug Administration (“FDA”) and conditional approval from the European Commission, China National Medical Products Administration (“NMPA”) and Health Canada for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy. We are pursuing expansion of ZYNLONTA internationally, and into earlier lines of diffuse large B-cell lymphoma (“DLBCL”)…
AI summary unavailable — showing raw filing excerpt
Generated from ADCT's filing dated 2026-03-10
Key risks
Table of Contents Item 1A. Risk Factors Our business faces significant risks and uncertainties. You should carefully consider all of the information set forth in this Annual Report and in other documents we file with or furnish to the SEC, including the following risk factors, before deciding to invest in or to maintain an investment in our securities. Our business, as well as our reputation, financial condition, results of operations, and share price, could be materially adversely affected by any of these risks, as well as other risks and uncertainties not currently known to us or not currently considered material. Risk Factors Summary Our ability to implement our business strategy is…
AI summary unavailable — showing raw filing excerpt
Generated from ADCT's filing dated 2026-03-10
Profitability
Operating margin
-149.3%
19.0%Net margin
-175.3%
21.3%Return on equity
76.7%
1.5%Return on assets
-44.1%
10.0%Leverage
Debt / equity
-2.74×
5.8%Long-term debt / equity
-0.61×
7.9%Debt / assets
157.5%
3.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $20.0M | +15.1% | $-33.0M | +14.6% | -164.6% |
Q4 2025 2025-12-31 | $30.1M | +67.9% | $-6.4M | +79.1% | -21.3% |
Q3 2025 2025-09-30 | $15.8M | -12.6% | $-41.0M | +6.8% | -260.1% |
Q2 2025 2025-06-30 | $18.1M | +6.2% | $-56.6M | -55.0% | -313.2% |
Q1 2025 2025-03-31 | $17.4M | -2.5% | $-38.6M | +17.2% | -221.8% |
Q4 2024 2024-12-31 | $17.9M | — | $-30.7M | — | -171.2% |
Q3 2024 2024-09-30 | $18.0M | +26.3% | $-44.0M | +5.9% | -244.1% |
Q2 2024 2024-06-30 | $17.0M | -11.3% | $-36.5M | +25.3% | -214.6% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ADCT — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$111.8M
Insider selling
$19.6M
Net activity
+$92.1M
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ADCT
Institutional value
$42.3M
Total shares held
11.7M
Distinct holders
53
-62 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6.3M | $23.4M | +823.4K (+15.2%) | Added |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.0M | $3.9M | — | New |
| 3 | BNP PARIBAS FINANCIAL MARKETS | 860.5K | $3.2M | +29.6K (+3.6%) | Added |
| 4 | JPMORGAN CHASE & CO | 489.1K | $1.8M | +17.4K (+3.7%) | Added |
| 5 | UBS Group AG | 458.9K | $1.7M | +243.7K (+113.2%) | Added |
| 6 | WELLS FARGO & COMPANY/MN | 262.8K | $985.4K | -57.3K (-17.9%) | Trimmed |
| 7 | Russell Investments Group, Ltd. | 254.9K | $955.9K | +230.4K (+939.1%) | Added |
| 8 | Bank of New York Mellon Corp | 202.3K | $758.5K | +29.3K (+16.9%) | Added |
| 9 | Walleye Capital LLC | 154.8K | $580.4K | — | New |
| 10 | Nuveen, LLC | 146.3K | $548.5K | +27.3K (+23.0%) | Added |
| 11 | JANE STREET GROUP, LLC | 142.1K | $532.7K | -57.7K (-28.9%) | Trimmed |
| 12 | KINGSWOOD WEALTH ADVISORS, LLC | 105.1K | $394.2K | +107 (+0.1%) | Added |
| 13 | RHUMBLINE ADVISERS | 104.1K | $390.2K | +13.4K (+14.7%) | Added |
| 14 | Wilmington Savings Fund Society, FSB | 100.0K | $375.0K | +0 (+0.0%) | No change |
| 15 | VANGUARD FIDUCIARY TRUST CO | 88.9K | $333.4K | — | New |
| 16 | DEUTSCHE BANK AG\ | 80.2K | $300.8K | +9.4K (+13.3%) | Added |
| 17 | Creative Planning | 79.0K | $296.4K | -34.2K (-30.2%) | Trimmed |
| 18 | Invesco Ltd. | 41.6K | $156.1K | +1.4K (+3.5%) | Added |
| 19 | Magnetar Financial LLC | 39.1K | $146.6K | +0 (+0.0%) | No change |
| 20 | SEI INVESTMENTS CO | 33.5K | $125.5K | +10.5K (+45.6%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ADCT's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.